NCT03820908View on ClinicalTrials.gov

Bisantrene for Relapsed /Refractory AML

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

May 19, 2020

Study Completion Date

July 22, 2020

Conditions
Acute Myelogenous LeukemiaAllogeneic Stem Cell Transplantation
Interventions
DRUG

Bisantrene

The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.

Trial Locations (1)

57261

Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
collaborator

Race Oncology Ltd

INDUSTRY

lead

Sheba Medical Center

OTHER_GOV

NCT03820908 - Bisantrene for Relapsed /Refractory AML | Biotech Hunter | Biotech Hunter